What's behind Labcorp's latest stock surge?

Traders Union
All News
Stocks
Labcorp surges 10.43% today to $365.73

Highlights

Labcorp reported third-quarter revenue of $3.81 billion, up 6.9% year over year and above expectations.
Adjusted EPS rose 14.5% to $4.78, with the company raising full-year revenue and profit guidance and declaring a cash dividend.
Shares of Labcorp climbed 10.43% to $365.73 with strong bullish technical signals, while multiple indicators show overbought conditions and resistance at $400.19.

Guidance raise and new partnership as earnings and expansion boost outlook

Labcorp reported third-quarter 2026 revenue of $3.81 billion, representing a 6.9% year-over-year increase and exceeding analyst estimates. Adjusted earnings per share rose 14.5% to $4.78, and the company raised its full-year guidance for both revenue and EPS. Labcorp also declared a quarterly cash dividend and announced a collaboration to expand diagnostics capabilities with the BD Onclarity HPV assay.

Anton Kharitonov, expert at Traders Union, believes Labcorp’s rally is overextended. He notes that while earnings and guidance exceeded consensus, several oscillators now signal overbought conditions. Kharitonov points out the upside gap and current volatility heighten the risk of a near-term pullback. He is cautious as consolidation near $365.56 may not hold if bearish momentum emerges. "Buyers may dominate now, but the technicals suggest investors should prepare for a retracement or pause."

Viktoras Karapetjanc, expert at Traders Union, sees Labcorp’s fundamentals as a strong catalyst for further growth. He focuses on the decisive revenue beat and guidance upgrade, which reinforce a bullish structure. Karapetjanc highlights the clear momentum above major moving averages and robust EPS expansion. He expects the partnership news to support long-term value creation. "Labcorp shows the right combination of operational strength and investor confidence — the market offers multiple setups for continued upside."

Sholanke Dele, market strategist, remains wary of the recent surge. He observes that intraday volatility at 7.08% and the overbought status of key oscillators expose Labcorp to downside risk. Dele is skeptical that the current gains will be sustained without a short-term shakeout. "Momentum looks powerful here, but patience is needed as corrections often follow such sharp spikes in price."

Persistent upside momentum as overbought signals flag pullback risk

Labcorp is trading firmly above the 20-day ($317.74), 50-day ($321.14), and 200-day ($285.93) moving averages. This positioning signals confirmation of bullish momentum in the short, medium, and long term, with the Ichimoku Kijun at $317.52 acting as trend confirmation support. The nearest resistance is at $400.19, with support set by the current high at $365.56. Momentum indicators present mixed signals: MACD is in buy territory, indicating continued upside potential, while the Average Directional Index (ADX) shows a neutral trend strength. The Relative Strength Index (RSI) reads 64.68 with a buy forecast, but the Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power (BBP) all indicate the stock is overbought. BBP at 8.85 confirms buyers currently dominate intraday momentum. The Awesome Oscillator signals buy, supporting the upward move. Labcorp surged to $365.73, rising $34.56 or 10.43%, and opened with an upside gap of approximately $13.38 (4.04%) before staying near session highs. Intraday volatility stands at 7.08%. Momentum and oscillators broadly reinforce strong intraday bullish tone, though several overbought signals highlight the risk of a short-term pause or pullback.

Previously it was reported that Labcorp shares came under pressure after U.S. regulatory changes signaled reimbursement cuts for laboratory services. The latest earnings-driven surge and technical breakout highlight a shift in market focus toward operational performance, with the stock’s ability to maintain levels above $358.31 now a key indicator for sustaining the current uptrend.

Source of Data: LH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.